It has been another busy year for Canadian Cancer Trials Group at the American Society of Clinical Oncology Annual Meeting. This conference brings together oncology professionals from around the world to discuss state-of-the-art treatments, new therapies with the best minds in the field of cancer research.

CCTG is well represented on this world stage with three recognition awards, fifteen poster presentations, and four oral abstracts. See below for more details.

For more information on the event see the [ASCO 2017 website](https://www.asco.org) or you can follow the conversation on our twitter account [@CDNCancerTrial #ASCO17](https://twitter.com/CDNCancerTrial/status/870670947073008896)

**Recognition Awards**

**Fellow of the American Society of Clinical Oncology**

- Frances A. Shepherd, MD, Princess Margaret Cancer Centre, University Health Network, Toronto

**International Women Who Conquer Cancer Mentorship Award**

- Mary Gospodarowicz, MD, FRCR, FRCPC, University of Toronto, Princess Margaret
2017 Career Development Award

- Scott V. Bratman, MD, PhD, Princess Margaret Cancer Centre

Oral Abstract

**CCTG OV.18 / MRC ICON6** - *Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer*

- **Session Title:** Gynecologic Cancer
- **Date:** Friday, June 2
- **Session Type:** Oral Abstract Session
- **Time:** 3:00 PM - 6:00 PM – Abstract presentation @ 5:00 PM
- **Location:** S406, Abstract #5506

**Abstract**


**CCTG CL.3/CALGB 10404 (Alliance) - A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance)**

- **Session Title:** Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
- **Date:** Saturday, June 3
- **Session Type:** Oral Abstract Session - Abstract presentation @ 4:00 PM
- **Time:** 3:00 PM - 6:00 PM
- **Location:** S100bc, Abstract #7503


**Abstract**
CCTG MAC.13 / BIG 2-06 / NCCTG (Alliance) N063D - Updated results from the phase III ALTTO trial comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T?L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer

- **Session Title:** Breast Cancer – Local/Regional/Adjuvant
- **Date:** Monday, June 5
- **Session Type:** Oral Abstract Session – Abstract presentation @ 10:09 AM
- **Time:** 9:45 AM to 12:45 PM
- **Location:** Hall D2; Abstract #502


Abstract

CCTG MA.34 / BIG 4-11 - APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with HER2-positive early breast cancer

- **Session Title:** Breast Cancer – Local/Regional/Adjuvant
- **Date:** Monday, June 5
- **Session Type:** Oral Abstract Session – Abstract presentation @ 9:45 AM
- **Time:** 9:45 AM to 12:45 PM
- **Location:** Hall D2; Abstract #LBA500


Abstract

CCTG MEC.3/E1609 - A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: Preliminary safety and efficacy of the ipilimumab arms
Ahmad A. Tarhini, Sandra J. Lee, F. Stephen Hodi, Uma N. M. Rao, Gary I Cohen, Omid Hamid, Laura Fulper Hutchins, Jeffrey Alan Sosman, Harriet M. Kluger, Vernon K. Sondak, Henry B. Koon, Donald P. Lawrence, Kari Lynn Kendra, David R. Minor, Carrie B. Lee, Mark R Albertini, Lawrence E. Flaherty, Teresa M. Petrella, John M. Kirkwood

Abstract

**CCTG EN.7 / (DCGOG PORTEC-3)** - Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.

- Session Title: Gynecologic Cancer
- Date: Friday, June 2
- Session Type: Oral Abstract Session
- Time: 3:00 PM - 6:00 PM – Abstract presentation @ 5:00 PM
- Location: S406, Abstract #5502


Abstract

**Poster Session**

**CCTG** - Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer

- Session Title: Lung Cancer – Non-Small Cell Metastatic
- Date: Saturday, June 3
- Session Type: Poster Session
- Time: 8:00 AM to 11:30 AM
- Location: Hall A, Abstract #9024; Poster Board #350

Abstract
Cetuximab clearance and survival in patients with metastatic colorectal cancer

- **Session Title:** Gastrointestinal (Colorectal) Cancer
- **Date:** Saturday, June 3
- **Session Type:** Poster Session
- **Time:** 8:00 AM to 11:30 AM
- **Location:** Hall A, Abstract #3600; Poster Board #223

**Abstract:** Di Maria Jiang, Hao-Wen Sim, Lillian L. Siu, Jeremy David Shapiro, Geoffrey Liu, Timothy Jay Price, Derek J. Jonker, Christos Stelios Karapetis, Andrew Strickland, Wenjiang Zhang, Mark Jeffery, Dongsheng Tu, Siobhan Ng, Sabe S. Sabesan, Jenny Shannon, Amanda Rose Townsend, Eric Morgen, Wei Xu, Christopher J. O'Callaghan, Eric Xueyu Chen

**CCTG CO.17/CO.20 - Age as a predictive and prognostic factor for targeted therapy treatment in metastatic chemorefractory colorectal cancer: An analysis of NCIC CTG CO.17 and CO.20.**

- **Session Title:** Gastrointestinal (Colorectal) Cancer
- **Date:** Saturday, June 3
- **Session Type:** Poster Session
Abstract

Connor Wells, Lillian L. Siu, Jeremy David Shapiro, Dongsheng Tu, Derek J. Jonker, Christos Stelios Karapetis, John Simes, Geoffrey Liu, Timothy Jay Price, Niall C. Tebbutt, Christopher J. O'Callaghan

CCTG CO.26 A phase II randomized study of durvalumab plus tremelimumab and best supportive care (BSC) vs BSC alone in patients with advanced colorectal carcinoma refractory to standard therapies

Abstract

Eric Xueyu Chen, Derek J. Jonker, Hagen F. Kennecke, Sheryl L. Koski, Alice Chia-chi Wei, Nadine M Magoski, Dongsheng Tu, Christopher J. O'Callaghan
CCTG GA.3 / AGO315OG - Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer - An international study organized by the Australasian Gastrointestinal Trials Group

Session Title: Gastrointestinal (Noncolorectal) Cancer

Date: Saturday, June 3

Session Type: Poster Session

Time: 8:00 AM to 11:30 AM

Location: Hall A, Abstract #TPS4136; Poster Board #125b

Katrin Marie Sjoquist, Nick Pavlakis, Andrew James Martin, Eric Tsobanis, Sonia Yip, Yung-Jue Bang, Thierry Alcindor, Christopher J. O’Callaghan, Kohei Shitara, Tanios S. Bekaii-Saab, Axel Grothey, Li-Tzong Chen, John Simes, John Raymond Zalcberg, David Goldstein

Abstract

CCTG CRC.2 / NCCTG N0147 (Alliance) - Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy
Frank A. Sinicrope, Qian Shi, Thomas C. Smyrk, Richard M. Goldberg, Erica N Heying, Steven J. Cohen, Sharlene Gill, Morton S. Kahlenberg, Suresh Nair, Anthony Frank Shields, Daniel J. Sargent, Balkrishna N. Jahagirdar, Michael N. Pollak, Steven R. Alberts

Abstract

### Association of immune markers and Immunoscore with survival of stage III colon carcinoma patients treated with adjuvant FOLFOX

- **Session Title:** Gastrointestinal (Colorectal) Cancer
- **Date:** Saturday, June 3
- **Session Type:** Poster Session
- **Time:** 8:00 AM - 11:30 AM
- **Location:** Hall A, Abstract #3516; Poster Board #139

Frank A. Sinicrope, Qian Shi, Fabienne Hermitte, Erica N Heying, Al Bowen Benson, Sharlene Gill, Richard M. Goldberg, Morton S. Kahlenberg, Suresh Nair, Anthony Frank Shields, Daniel J. Sargent, Jerome Galon, Steven R. Alberts

Abstract

### Genetic correlates of therapeutic toxicities of stage III colon carcinoma patients treated with adjuvant FOLFOX +/- cetuximab

- **Session Title:** Gastrointestinal (Colorectal) Cancer
- **Date:** Saturday, June 3
- **Session Type:** Poster Session
- **Time:** 8:00 AM - 11:30 AM
- **Location:** Hall A, Abstract #3604; Poster Board #227

Polly A. Newcomb, Wei Sun, Xinwei Hua, Barbara L. Banbury, Amanda I. Phipps, Jonathan Kocarnik, Tabitha A. Harrison, Qian Shi, Frank A. Sinicrope, Stephen N. Thibodeau, Emily Chan, Sharlene Gill, Richard M. Goldberg, Morton S. Kahlenberg, Suresh Nair, Anthony Frank Shields, Balkrishna N. Jahagirdar, Ulrike Peters, Steven R. Alberts, Andrew T. Chan

Abstract
CCTG PA.7 - A randomized phase II study of gemcitabine and nab-paclitaxel vs. gemcitabine, nab-paclitaxel, durvalumab, and tremelimumab as 1st line therapy in metastatic pancreatic ductal adenocarcinoma

- Session Title: Gastrointestinal (Noncolorectal) Cancer
- Date: Saturday, June 3
- Session Type: Poster Session
- Time: 8:00 AM - 11:30 AM
- Location: Hall A, Abstract #TPS4149; Poster Board #132a

Daniel John Renouf, Petr Kavan, Neesha C. Dhani, Derek J. Jonker, Alice Chia-chi Wei, Tina Hsu, Patricia A. Tang, Barbara Graham, Dongsheng Tu, Christopher J. O'Callaghan

Abstract

Accrual of older adults to Canadian Cancer Trials Group-led trials: A retrospective analysis from 1990 to 2015

- Session Title: Patient and Survivor Care
- Date: Saturday, June 3
Catalina Hernandez Torres, Winson Y. Cheung, Christopher J. O'Callaghan, Tina Hsu

**Abstract**

CCTG SC.24 - *A randomized phase II/III study comparing stereotactic body radiotherapy versus conventional palliative radiotherapy for patients with spinal metastases*
CCTG IND.226 - Immune-related adverse events with platinum chemotherapy with - durvalumab ± tremelimumab

- Session Title: Developmental Therapeutics – Immunotherapy
- Date: Monday, June 5
- Session Type: Poster Session
- Time: 8:00 AM to 11:30 AM
- Location: Hall A, Abstract #3058; Poster Board #153

Nathalie Daaboul, Isabelle Gauthier, Dongsheng Tu, Pamela Brown-Walker, Xiaojun Sun, Desiree Hao, Rosalyn A. Juergens, Penelope Ann Bradbury, Mihaela Mates, Mustapha Ali Tehfe, Christian K. Kollmannsberger, Peter Michael Ellis, Andrew George Robinson, Paul Wheatley-Price, Scott Andrew Laurie, Lesley Seymour
Validation of RECIST 1.1 for use with cytotoxic agents and targeted cancer agents: Results of a RECIST Working Group analysis of a 50 clinical trials pooled individual patient database

- **Session Title:** Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
- **Date:** Monday, June 5
- **Session Type:** Poster Session
- **Time:** 8:00 AM to 11:30 AM
- **Location:** Hall A; Abstract #2534; Poster Board #26

Saskia Litière, Gaëlle Isaac, Elisabeth De Vries, Jan Bogaerts, Alice P. Chen, Janet Dancey, Robert Ford, Steve J Gwyther, Otto S. Hoekstra, Erich Huang, Nancy U Lin, Yan Liu, Sumithra J. Mandrekar, Lawrence HOWARD Schwartz, Lalitha Shankar, Patrick Therasse, Lesley Seymour

**Abstract**

**CCTG HN.6 - Resource utilization in patients with head and neck cancer: Analysis of CCTG HN.6 (NCT00820248)**

- **Session Title:** Head and Neck Cancer
- **Date:** Monday, June 5
- **Session Type:** Poster Session
- **Time:** 1:15 PM to 4:45 PM
- **Location:** Hall A, Abstract #6067; Poster Board #55


**Abstract**

**CCTG IND.209 - A randomized phase II study of pelareorep plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer**

- **Session Title:** Genitourinary (Prostate) Cancer
- **Date:** Monday, June 5
- **Session Type:** Poster Session
- **Time:** 1:15 PM to 4:45 PM
- **Location:** Hall A; Abstract #5021; Poster Board #95

Bernhard J. Eigl, Eric Winquist, Dongsheng Tu, Sebastien J. Hotte, Christina M. Canil, Richard William Gregg, Muhammad Zulfiqar, Scott A. North, Susan Ellard, Joseph D. Ruether, Lyly H.
CCTG MAC.11/S0221 - SWOG S0221 updated: Randomized comparison of chemotherapy schedules in breast cancer adjuvant therapy.

- Session Title: Breast Cancer—Local/Regional/Adjuvant
- Date: Sunday, June 4
- Session Type: Poster Session (Board #121)
- Time: 8:00 AM to 11:30 AM
- Location: Hall A - Abstract #521